CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
December 07, 2017
|
|
November 15, 2017
 The MEC.5 trial, A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma, is closed further accrual as of November 2nd, 2017. This trial met its accrual goal and was subsequently closed to registrations. Read More |
 OVC.1 (NRG GY004) A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer has been closed to accrual as of Nov 10, 2017.
|
 Celebrating a fantastic milestone for the CX.5 SHAPE trial with over 400 patients randomized world wide. Read More |
|
|
November 01, 2017
 GAC.1 trial: Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma, has been permanently closed by the lead group.
|
Canadian Cancer Research Alliance announces award winnersPublished: November 01, 2017Category: News  Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award. Read More |
 Introducing the new CCTG Group Bulletin format, please share your thoughts with us so we can make adjustments and improvements. Read More |